Tumor-derived TGF-β suppresses CD80 and CD86 costimulatory molecule expression by DCs and promotes the development of a PD-L1-expressing immunosuppressive DC subset capable of inhibiting CD8+ T cell activity in a metastatic ovarian cancer model (32, 33, 67). Here, CD86 is linked to neoplasm.